Cargando…

Engaging with the private healthcare sector for the control of tuberculosis in India: cost and cost-effectiveness

BACKGROUND: The control of tuberculosis (TB) in India is complicated by the presence of a large, disorganised private sector where most patients first seek care. Following pilots in Mumbai and Patna (two major cities in India), an initiative known as the ‘Public–Private Interface Agency’ (PPIA) is n...

Descripción completa

Detalles Bibliográficos
Autores principales: Arinaminpathy, Nimalan, Nandi, Arindam, Vijayan, Shibu, Jha, Nita, Nair, Sreenivas A, Kumta, Sameer, Dewan, Puneet, Rade, Kiran, Vadera, Bhavin, Rao, Raghuram, Sachdeva, Kuldeep S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8493898/
https://www.ncbi.nlm.nih.gov/pubmed/34610905
http://dx.doi.org/10.1136/bmjgh-2021-006114
_version_ 1784579207935819776
author Arinaminpathy, Nimalan
Nandi, Arindam
Vijayan, Shibu
Jha, Nita
Nair, Sreenivas A
Kumta, Sameer
Dewan, Puneet
Rade, Kiran
Vadera, Bhavin
Rao, Raghuram
Sachdeva, Kuldeep S
author_facet Arinaminpathy, Nimalan
Nandi, Arindam
Vijayan, Shibu
Jha, Nita
Nair, Sreenivas A
Kumta, Sameer
Dewan, Puneet
Rade, Kiran
Vadera, Bhavin
Rao, Raghuram
Sachdeva, Kuldeep S
author_sort Arinaminpathy, Nimalan
collection PubMed
description BACKGROUND: The control of tuberculosis (TB) in India is complicated by the presence of a large, disorganised private sector where most patients first seek care. Following pilots in Mumbai and Patna (two major cities in India), an initiative known as the ‘Public–Private Interface Agency’ (PPIA) is now being expanded across the country. We aimed to estimate the cost-effectiveness of scaling up PPIA operations, in line with India’s National Strategic Plan for TB control. METHODS: Focusing on Mumbai and Patna, we collected cost data from implementing organisations in both cities and combined this data with models of TB transmission dynamics. Estimating the cost per disability adjusted life years (DALY) averted between 2014 (the start of PPIA scale-up) and 2025, we assessed cost-effectiveness using two willingness-to-pay approaches: a WHO-CHOICE threshold based on per-capita economic productivity, and a more stringent threshold incorporating opportunity costs in the health system. FINDINGS: A PPIA scaled up to ultimately reach 50% of privately treated TB patients in Mumbai and Patna would cost, respectively, US$228 (95% uncertainty interval (UI): 159 to 320) per DALY averted and US$564 (95% uncertainty interval (UI): 409 to 775) per DALY averted. In Mumbai, the PPIA would be cost-effective relative to all thresholds considered. In Patna, if focusing on adherence support, rather than on improved diagnosis, the PPIA would be cost-effective relative to all thresholds considered. These differences between sites arise from variations in the burden of drug resistance: among the services of a PPIA, improved diagnosis (including rapid tests with genotypic drug sensitivity testing) has greatest value in settings such as Mumbai, with a high burden of drug-resistant TB. CONCLUSIONS: To accelerate decline in TB incidence, it is critical first to engage effectively with the private sector in India. Mechanisms such as the PPIA offer cost-effective ways of doing so, particularly when tailored to local settings.
format Online
Article
Text
id pubmed-8493898
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-84938982021-10-14 Engaging with the private healthcare sector for the control of tuberculosis in India: cost and cost-effectiveness Arinaminpathy, Nimalan Nandi, Arindam Vijayan, Shibu Jha, Nita Nair, Sreenivas A Kumta, Sameer Dewan, Puneet Rade, Kiran Vadera, Bhavin Rao, Raghuram Sachdeva, Kuldeep S BMJ Glob Health Original Research BACKGROUND: The control of tuberculosis (TB) in India is complicated by the presence of a large, disorganised private sector where most patients first seek care. Following pilots in Mumbai and Patna (two major cities in India), an initiative known as the ‘Public–Private Interface Agency’ (PPIA) is now being expanded across the country. We aimed to estimate the cost-effectiveness of scaling up PPIA operations, in line with India’s National Strategic Plan for TB control. METHODS: Focusing on Mumbai and Patna, we collected cost data from implementing organisations in both cities and combined this data with models of TB transmission dynamics. Estimating the cost per disability adjusted life years (DALY) averted between 2014 (the start of PPIA scale-up) and 2025, we assessed cost-effectiveness using two willingness-to-pay approaches: a WHO-CHOICE threshold based on per-capita economic productivity, and a more stringent threshold incorporating opportunity costs in the health system. FINDINGS: A PPIA scaled up to ultimately reach 50% of privately treated TB patients in Mumbai and Patna would cost, respectively, US$228 (95% uncertainty interval (UI): 159 to 320) per DALY averted and US$564 (95% uncertainty interval (UI): 409 to 775) per DALY averted. In Mumbai, the PPIA would be cost-effective relative to all thresholds considered. In Patna, if focusing on adherence support, rather than on improved diagnosis, the PPIA would be cost-effective relative to all thresholds considered. These differences between sites arise from variations in the burden of drug resistance: among the services of a PPIA, improved diagnosis (including rapid tests with genotypic drug sensitivity testing) has greatest value in settings such as Mumbai, with a high burden of drug-resistant TB. CONCLUSIONS: To accelerate decline in TB incidence, it is critical first to engage effectively with the private sector in India. Mechanisms such as the PPIA offer cost-effective ways of doing so, particularly when tailored to local settings. BMJ Publishing Group 2021-10-05 /pmc/articles/PMC8493898/ /pubmed/34610905 http://dx.doi.org/10.1136/bmjgh-2021-006114 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.
spellingShingle Original Research
Arinaminpathy, Nimalan
Nandi, Arindam
Vijayan, Shibu
Jha, Nita
Nair, Sreenivas A
Kumta, Sameer
Dewan, Puneet
Rade, Kiran
Vadera, Bhavin
Rao, Raghuram
Sachdeva, Kuldeep S
Engaging with the private healthcare sector for the control of tuberculosis in India: cost and cost-effectiveness
title Engaging with the private healthcare sector for the control of tuberculosis in India: cost and cost-effectiveness
title_full Engaging with the private healthcare sector for the control of tuberculosis in India: cost and cost-effectiveness
title_fullStr Engaging with the private healthcare sector for the control of tuberculosis in India: cost and cost-effectiveness
title_full_unstemmed Engaging with the private healthcare sector for the control of tuberculosis in India: cost and cost-effectiveness
title_short Engaging with the private healthcare sector for the control of tuberculosis in India: cost and cost-effectiveness
title_sort engaging with the private healthcare sector for the control of tuberculosis in india: cost and cost-effectiveness
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8493898/
https://www.ncbi.nlm.nih.gov/pubmed/34610905
http://dx.doi.org/10.1136/bmjgh-2021-006114
work_keys_str_mv AT arinaminpathynimalan engagingwiththeprivatehealthcaresectorforthecontroloftuberculosisinindiacostandcosteffectiveness
AT nandiarindam engagingwiththeprivatehealthcaresectorforthecontroloftuberculosisinindiacostandcosteffectiveness
AT vijayanshibu engagingwiththeprivatehealthcaresectorforthecontroloftuberculosisinindiacostandcosteffectiveness
AT jhanita engagingwiththeprivatehealthcaresectorforthecontroloftuberculosisinindiacostandcosteffectiveness
AT nairsreenivasa engagingwiththeprivatehealthcaresectorforthecontroloftuberculosisinindiacostandcosteffectiveness
AT kumtasameer engagingwiththeprivatehealthcaresectorforthecontroloftuberculosisinindiacostandcosteffectiveness
AT dewanpuneet engagingwiththeprivatehealthcaresectorforthecontroloftuberculosisinindiacostandcosteffectiveness
AT radekiran engagingwiththeprivatehealthcaresectorforthecontroloftuberculosisinindiacostandcosteffectiveness
AT vaderabhavin engagingwiththeprivatehealthcaresectorforthecontroloftuberculosisinindiacostandcosteffectiveness
AT raoraghuram engagingwiththeprivatehealthcaresectorforthecontroloftuberculosisinindiacostandcosteffectiveness
AT sachdevakuldeeps engagingwiththeprivatehealthcaresectorforthecontroloftuberculosisinindiacostandcosteffectiveness